Bellus Medical is proud to announce the acquisition of Healeon Medical, Inc.’s HD PRP system for the aesthetic marketplace. This specialized system is designed to meet the demands of busy practices seeking higher volume and higher yield Platelet Rich Plasma procedures; with the most efficient and convenient system on the market. As part of their expanding Platelet Rich Plasma portfolio, Bellus Medical will re-brand their suite of offerings as the ProGen PRP™ Advantage and ProGen PRP™ Versa lines; both high-yield systems for use in Platelet Rich Plasma procedures.
Dedicated to technology, innovation, education and customer service, the acquisition of Healeon’s HD PRP platform positions Bellus as a top provider in the US Platelet Rich Plasma market with the most comprehensive and flexible product lines. Bellus’ expanded Platelet Rich Plasma portfolio, including ProGen PRP™ Advantage, offers the lowest cost per milliliter and greatest ROI for providers across the industry.
“One of the core pillars of Bellus Medical is innovation and continuing technological advancements. Expanding our Platelet Rich Plasma portfolio with a system that addresses the needs of high-volume practices uniquely positions us to add immediate value to the market,” says Joe Proctor, Founder and President of Bellus Medical.
“Healeon is proud of its newly announced partnership with Bellus Medical, offering best-in-class treatment options across the industry,” says Jeff Greiner, CEO of Healeon Medical.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Healeon Medical of Newbury Park, California develops and commercializes next generation innovative medical devices and offers clinical expertise and education to medical professionals in the regenerative medicine market. Healeon has signed a partnership with Bellus Medical to provide their proprietary, cutting-edge Healeon HD PRP technology featuring an innovative high platelet capture design.
“We strive to always provide our patients with gold standard therapies,” said Jeff Bedard, President and CEO of Crown Laboratories. “Platelet Rich Plasma has quickly become an ideal treatment for many dermatology patients. We are delivering on our core principles of technology and putting our customer first.”
Date: May 28, 2019
Source: Cision
